Phase I/II trial of intermittent subcutaneous IL-2 administration in pediatric patients with moderate immune suppression: Results of Pediatric AIDS Clinical Trials Study 402

• Published in: Journal of allergy and clinical immunology 2007-06, Vol.119 (6), p.1538-1541
• Main Authors: Pahwa, Savita, MD, Muresan, Petronella, MS, Sleasman, John, MD, Fenton, Terry, EdD, Moye, John, MD, Deveikis, Audra, MD, Wara, Diane, MD, Van Dyke, Russ, MD
• Format: Article
• Language: English
• Subjects: Acquired immune deficiency syndrome; Acquired Immunodeficiency Syndrome - drug therapy; Acquired Immunodeficiency Syndrome - immunology; Acquired Immunodeficiency Syndrome - virology; Adolescent; AIDS; Allergy and Immunology; Anti-HIV Agents - therapeutic use; Antiretroviral drugs; CD4 Lymphocyte Count; Child; Children & youth; Dose-Response Relationship, Immunologic; Drug therapy; HIV; Human immunodeficiency virus; Humans; Immunosuppressive Agents - administration & dosage; Injections, Subcutaneous; Interleukin-2 - administration & dosage; Interleukin-2 - adverse effects
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/j.jaci.2006.12.674

IL-2, a cytokine produced by activated T cells,1 can significantly increase CD4 T-cell counts in HIV-infected adults.2-6 Cyclical IL-2 therapy expands naive and central memory CD4 T cells and increases their survival.6,7 Toxicities observed with the intravenous route2,8 have been reduced by cyclic subcutaneous administration.3,4 Information on appropriate dosing of subcutaneous IL-2 in HIV-infected children is lacking. The Pediatric AIDS Clinical Trials Group 402 study was a multicenter dose-escalation trial to determine the highest tolerated dose of subcutaneous IL-2 in HIV-infected children and adolescents with moderate immune suppression.